COUGH SUPPRESSANT DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

A cough is a most common symptom of various upper and lower respiratory tract infections. It affects a large proportion of the population leading them to seek medical attention. According to the data published by Journal of the Association of Physicians of India in 2016, cough was identified as the sixth most common reason for hospital outpatient department visits. Cough suppressants, also known as antitussives, are medications that help to suppress cough. Some of the examples of cough suppressants are Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, and Pholcodine. Dextromethorphan and Codeine are the most common and widely used cough suppressant in market.

Market Dynamics

Frequent launch of new cough suppressants in the market by key players is expected to drive the cough suppressant drugs market growth over the forecast period. For instance, in March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.

Various key players in the market are conducting research and are evaluating safety and efficacy of various drugs for the treatment of cough. Such initiatives taken by companies is expected to lead to the development of new cough suppressant drugs.

For instance, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is evaluating the efficacy and safety of benzonatate soft capsules for improving adult cough symptoms, wherein the study is currently (2018) under phase 3 clinical trial.

Moreover, high prevalence of cough is expected to increase the demand for cough suppressant drugs, thereby driving the market growth. For instance, according to the study published by the National Center for Biotechnology Information in 2013, cough is a very common condition and around 12% of the people in Britain experience chronic cough, daily or weekly.

Key features of the study

• This report provides in-depth analysis of cough suppressant drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2026 – 2033), considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by leading players
• It profiles leading players in the global cough suppressant drugs market  based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global cough suppressant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the cough suppressant drugs market

Market Segmentation

• Disease Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Dry Cough
  • Wet Cough
• Drug Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Dextromethorphan
  • Codeine
  • Noscapine
  • Butamirate
  •  Benzonatate
  • Pholcodine
  •  Others
• Product Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Over-the-counter (OTC)
  • Prescription Drug
• Age Group Insights (Revenue, USD Mn, 2026 - 2033)
  • Pediatric
  • Adult
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
  • Hospital
  • Retail Pharmacy
  • Online Pharmacy
  • Others
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Perrigo Company plc
  • Vernalis plc
  • Tris Pharma Inc.
  • Pfizer Inc.
  • Aytu BioScience, Inc.
  • Acella Pharmaceuticals LLC
  • Mayne Pharma Inc.
  • Taro Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Ltd
  • GlaxoSmithKline plc.